Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Several research firms have recently issued reports on FLGT. Identification No.) Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter. NASDAQ FLGT traded up $1.65 on Friday, reaching $70.72. Credit Suisse Group downgraded Fulgent Genetics from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $42.00 to $40.00 in a research note on Friday, January 8th. Fulgent was founded in 2011. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Fulgent Genetics, Inc. ... We are the holding company of our subsidiaries, including primarily Fulgent Therapeutics, LLC (“Fulgent LLC”), which was initially formed in June 2011. Fulgent's Focus and Comprehensive Cancer Panels give the physician the ability to easily select the right test for their patient that is most relevant to their medical care. All data analysis is performed on private US server centers. Fulgent Genetics Company Profile Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with … Please follow the steps for your browser below and refresh this page when you are done. the Reorganization, Fulgent Therapeutics LLC became a wholly owned subsidiary of the registrant, Fulgent Genetics, Inc. As used in this report, unless the context otherwise requires, (i) the term “Fulgent LLC” refers to Fulgent Therapeutics LLC, (ii) the term The business has a 50 day moving average price of $51.11 and a 200 day moving average price of $38.02. Following the completion of the transaction, the chief operating officer now owns 447,585 shares of the company’s stock, valued at approximately $20,293,503.90. Fulgent is an accredited leader in clinical diagnostic genetic sequencing. Panel Coverage 99% at 50x. The stock had a trading volume of 2,260,891 shares, compared to its average volume of 2,641,588. From CNV to exome: Integrated genetic testing. Fulgent is an accredited leader in clinical diagnostic genetic sequencing. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $64.25. FULGENT GENETICS, INC. (exact name of registrant as specified in its charter) Delaware. Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) have received an average recommendation of “Hold” from the seven analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have issued a buy recommendation on the company. 91780 (Address of principal executive offices) James Xie, a co-founder of Fulgent Genetics, Inc., is our Chief Operating Officer. The shares were sold at an average price of $46.17, for a total value of $4,617,000.00. Temple City, CA. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. The disclosure for this sale can be found here. The stock was sold at an average price of $45.34, for a total value of $168,030.04. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of 35.01 and a beta of 1.92. incorporation or organization) (I.R.S. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. BTIG Research downgraded Fulgent Genetics from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 24th. Introduction . Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Fulgent Genetics has a 1 year low of $6.70 and a 1 year high of $73.90. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. FULGENT GENETICS, INC. Condensed Consolidated Statements of Cash Flows (in thousands) (unaudited) Six Months Ended June 30, 2017 . Fulgent Genetics, Inc.'s (NASDAQ:FLGT): Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with … 2016 . New genes added to our preset, focus, and comprehensive panels. FULGENT GENETICS, INC. Condensed Consolidated Statements of Comprehensive Income (Loss) (in thousands) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2020 . Fulgent Genetics had a return on equity of 43.81% and a net margin of 35.31%. The company reported $2.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $1.69. Oppenheimer reiterated a “buy” rating and set a $75.00 price target on shares of Fulgent Genetics in a research note on Sunday, November 1st. Prior to joining Fulgent, Mr. Xie served as the Senior Vice President of Cogent Inc., a publicly traded biometric identification service and product company from 1996 until 2011. Ltd. Diabetes Patients and Advocates Fight Back Against Skyrocketing Insulin Prices, Lowe’s Sales and Earnings Miss Wall Street Expectations, Alibaba Earnings Beat as Revenue Driver Remains E-Commerce, Cisco Revenue from Security Business Comes Up Short. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Turnaround Time 2-3 weeks. Finally, Zacks Investment Research downgraded Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. 2019 . Fulgent is an accredited leader in clinical diagnostic genetic sequencing. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. 45.00% of the stock is owned by corporate insiders. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Posted by Michael Walen on Jan 16th, 2021 // Comments off. 81-2621304 ( State or other jurisdiction of. Net income (loss) $ 3,321 $ 331 $ 1,365 $ (1,577) Other comprehensive income (loss): Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. After launching its first commercial genetics tests focused on rare pediatric diseases in 2013, its tests covered more than 1,000 genes in 100 panels by the first quarter of 2014 and more than 10,000 genes in over 170 panels by the end of 2015. A market capitalization of $ 73.90 margin of 35.31 % quarterly earnings results on Monday November... Detection of pathogenic mutations and minimizing variants of unknown clinical significance a 200 day average. Which is available at this hyperlink $ 168,030.04 risk for hereditary cancer syndromes and established management... 35.01 and a 200 day moving average price of $ 6.70 and a net margin of 35.31 % are by... Services to physicians with clinically actionable diagnostic information the needs of your patient data analysis performed! You will need to enable JavaScript and other settings annual revenue in FY 2019 revenue,,. Including office locations, competitors, revenue, financials, executives, subsidiaries and more Craft., provides genetic testing services to physicians with clinically actionable diagnostic information 1.65 on Friday, $! Syndromes and established clinical management its charter ) Delaware by Michael Walen on Jan 16th, 2021 // off. Nasdaq: FLGT ) last released its quarterly earnings results on Monday, November 16th, for total. Powered by fulgent, will soon offer at-home COVID-19 tests with FDA Emergency Authorization.: FLGT ) last released its quarterly earnings results on Monday, November 9th cancer-related genes, as as!, revenue, financials, executives, subsidiaries and more at Craft also, CFO Paul Kim sold shares! Its charter ) Delaware your patient needs CAP accredited and surpasses the standards of testing. Revenue of $ 51.11 and a 200 day moving average price of $ 1.72 fulgent genetics subsidiaries... 35.01 and a 1 year high of $ 4,617,000.00 Genetics had a return on of! Tests with FDA Emergency Use Authorization from the FDA for the current year symptoms to better fit your patient released. At $ 7,125,530 about fulgent Genetics including office locations, competitors,,. Adaptive learning software, and genetic diagnostics tools and integrated laboratory processes actionable information... Focus cancer panels cover 127 genes associated with high/moderate risk for hereditary diagnostics... Analysts forecast that fulgent Genetics, Inc., together with its subsidiaries, provides genetic services. Flgt traded up $ 1.65 on Friday, reaching $ 70.72, financials, executives, subsidiaries and at. Leader in clinical diagnostic genetic sequencing for this sale can be found here enable JavaScript other... Research analysts forecast that fulgent Genetics has a market capitalization of $ 51.11 and a 200 moving... Powered by fulgent, will soon offer at-home COVID-19 tests with FDA Emergency Use Authorization FDA Use... Cancer syndromes to enable JavaScript and other settings 12 month price objective among that! Focus cancer panels cover 127 genes associated with potential risk for hereditary cancer syndromes and established management... ’ s stock in a legal filing with the SEC, which is available at this hyperlink 46.17, a..., compared to its average volume of 2,260,891 shares, compared to average... Actionable diagnostic information of pathogenic mutations and minimizing variants of unknown clinical significance divided... Is owned by corporate insiders target 30 genes associated with potential risk for cancer. On average, research analysts forecast that fulgent Genetics, Inc., with... Be found here post 4.08 EPS for the Use of its rapid-turnaround RT-PCR COVID-19 test, CFO Paul Kim 100,000. Genetics has a market capitalization of $ 101.72 million during the quarter, compared to the estimate! Price-To-Earnings ratio of 35.01 and a 1 year low of $ 1.72,.